News Aptose Biosciences Inc. OTC Markets

Stocks

APTOF

CA03835T4081

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 11:53:32 2026-07-02 EDT			5-day change	1st Jan Change
1.690 ^USD	+0.90%		+9.03%	+14.19%

07-02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
06-29	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI

All News

Mentions Relevance

07-02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
06-30	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical	AQ
06-15	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML	CI
06-15	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026	MT
06-15	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
06-15	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
05-29	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June	MT
05-29	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed	RE
05-29	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
05-13	Aptose Biosciences: Q1 Earnings Snapshot	AQ
05-13	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Aptose Biosciences : Reports First Quarter 2026 Results	PU
05-13	Aptose Reports First Quarter 2026 Results	AQ
04-30	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
03-31	Aptose Biosciences: Q4 Earnings Snapshot	AQ
03-31	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction	MT
03-31	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights	AQ
03-31	Aptose Biosciences Inc. - Shareholder/Analyst Call
03-30	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt	CI
03-23	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement	RE
03-23	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical	MT
03-23	Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement	AQ
03-20	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote FOR Proposed Plan of Arrangement with Hanmi Pharmaceutical	AQ
03-19	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE